Pharmacy
School of Pharmacy
- Location
- Belfast, United Kingdom
- Funding
- See university guidance
- Application deadline
- See university guidance
About the project
My research focuses on improving treatment outcomes for women with ovarian cancer through functional precision pharmacology. We study drug behaviour across 2D, 3D, and immune cell co-culture models to evaluate systems-level responses to treatment. In parallel, we are developing high-throughput drug screening assays using patient-derived samples to assess tumour sensitivity to standard and repurposed agents, including identification of novel combination therapies. This work aims to drive innovation in guiding therapy selection in ovarian cancer.
- Dr Fiona Furlong: School of Pharmacy
Contact info
- View Academic Profile
- f.furlong@qub.ac.uk
- 02890 9097 0000
Research Interests
Open to PhD applications in the field of
Make a PhD enquiry
- Cancer Pharmacology
- Precision Medicine
- Translational Oncology
- Drug Repurposing/Experimental Therapies
- High Content Screening
- Cancer Cell Biology
Public outreach & key achievements
- Irish Cancer Society Research Fellow
- https://igcs.org/wp-content/uploads/2024/09/Advocacy-Poster-Booklet-2024Final.pdf
Research students
PhD Title | Evaluation of immunogenic cell death in ovarian cancer
Name | Mr Benjamin Pepperrell
Country | UK
Years of Study | 2023 - 2027
PhD Title | An investigation of novel interacting drug combinations in the treatment of ovarian cancer
Name | Dr Yu Sun
Country | China
Years of Study | 2022 - 2026
PhD Title | Investigation of the pathophysiological role of HDAC6 in triple negative breast cancer
Name | Dr Leen Asaad
Country | Jordan
Year of Study | 2021 - 2024
Alumni: Where are they now
PhD Title | Investigation of the pathophysiological role of HDAC6 in triple negative breast cancer
Name | Dr Leen Asaad
Years of Study | 2021 - 2024
Country | Jordan
Current Position | Assistant Professor in University of Petra, Jordan
PhD Title | The Evaluation of the effects of the Mitotic Arrest Deficiency Protein 2 (MAD2) and the miR-433 microRNA on Chemoresistance and Cancer Prognosis
Name | Dr Tara Byrne
Years of Study | 2013 - 2017
Country | Northern Ireland
Current Position | Clinical Supplies Manager at ICON
PhD Title | The contribution of the microRNA miR-433 to the pathology of ovarian cancer
Name | Dr Karolina Weiner-Gorzel
Years of Study | 2011 - 2014
Country | Poland
Current Position | Medical Oncology Registrar in St. Vincent’s University Hospital, Dublin, Ireland
Discover More
- Faculty of Medicine, Health & Life Sciences
- School of Pharmacy
- Materials and Advanced Technologies for Healthcare
- LinkedIn profile